NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability
- 20 November 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (26) , 5628-5639
- https://doi.org/10.1021/jm020160g
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Biaryl Ether Retrohydroxamates as Potent, Long-lived, Orally Bioavailable MMP InhibitorsBioorganic & Medicinal Chemistry Letters, 2001
- Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical TrialsAnnals of the New York Academy of Sciences, 1999
- Marimastat (BB2516): Current status of developmentCancer Chemotherapy and Pharmacology, 1999
- Matrix metalloproteinase inhibitors 1998Expert Opinion on Therapeutic Patents, 1998
- Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in RabbitsJournal of Medicinal Chemistry, 1997
- Discovering High-Affinity Ligands for Proteins: SAR by NMRScience, 1996
- Recent advances in matrix metalloproteinase inhibitor researchDrug Discovery Today, 1996
- .alpha.-Melanotropin: the minimal active sequence in the frog skin bioassayJournal of Medicinal Chemistry, 1987
- Captopril: Pharmacology, Metabolism, and DispositionDrug Metabolism Reviews, 1984